This report provides:
- An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Breakdowns of the market size of anticoagulants by revenue at manufacturers’ sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
- Discussion of research and development of antithrombotic/anticoagulant treatments
- Comprehensive company profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field.
The objectives of the study are to present both a comprehensive look at antithrombotics/anticoagulant drugs for treating thrombotic disease and global market measurements of both the overall market and all possible market segments, and to forecast market and segment growth over the next five years.
REASONS FOR STUDY
This BCC study is presented to increase the awareness of antithrombotic/ anticoagulant drugs to treat thrombotic disease and other diseases that are linked to thrombotic disease. The study analyzes (1) select antithrombotic/anticoagulant drugs for treating various thrombotic diseases in coronary artery disease, peripheral vascular disease, valvular heart disease, congestive heart failure and many others; (2) the marketing of these drugs in the global market from different standpoints; and (3) the issues and trends affecting the market.
Antithrombotic/anticoagulant manufacturers, driven by both research breakthroughs and increased recognition of expanding market opportunities, have stepped up the pace of development of products. Because of the evolving nature of this important area of study, executives of product development for antithrombotic/anticoagulant drugs must remain ever vigilant of the changing environment and strive to keep abreast of new and currently used modalities in all facets of the market.
SCOPE OF STUDY
This report is a comprehensive business tool designed to provide an in-depth look at antithrombotic/anticoagulant drugs for various cardiovascular applications. The geographic scope of the report is global with a special emphasis on individual regions such as the United States, Europe, Japan and Rest of World. The report describes the industry, its relationship to the healthcare industry and its participants, and trends for the future.
Categories discussed in the report include:
- Anticoagulants
- Antiplatelets
- Thrombin inhibitors
All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2012 to 2017 and assessing the competitors and competitor market shares.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary research sources, including executives, product managers, and clinical specialists in the congestive heart failure drug development arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of thrombotic and cardiovascular disease.
Key information from published literature was used to conduct interviews with over 12 industry participants to validate and obtain expert opinions on current and future trends in the antithrombotic/anticoagulant drug market. Interviews were the primary basis for information regarding development of market size and were obtained by email and telephone. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.
All market data pertain to the global market at the manufacturer’s level. Data are expressed in current U.S. dollars. The base year was 2012. Historical data are provided for 2011 and forecast data are provided for 2017. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2012 base year.
ANALYST CREDENTIALS
Mary Anne Crandall is an expert industry analyst specializing in the medical pharmaceutical and device industry for the last 20 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical and medical device industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology and is currently working on a PhD.